LBL-007
Phase 3Small molecule
BeiGeneLBL-007 is one of 164 small molecule programs targeting Advanced Malignancies. It is currently in Phase 3.
6
Indications
10
Total Trials
6
Active Trials
163
Competitors
Pipeline
Status by Indication[3][1]
Indication
Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerPreclinical
Active, not recruiting
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Supportive Care Measures
Merck & Co.Phase 3
LBL-007
BeiGenePhase 3
JMT101
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Melanoma2 trials
Advanced Malignancies1 trial
Advanced Solid Tumors1 trial
Esophageal Squamous Cell Carcinoma1 trial
4 more indications
Advanced Malignant Tumors1 trial
Non-Small Cell Lung Cancer1 trial
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LBL-007. EMBL-EBI & Wellcome Sanger Institute.
- [4]